Project Grant R00HL163412
Award Date 8/11/25
Completion Date 7/31/28
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MI, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $511,135 to the University of California, Los Angeles (UCLA) for research on the structure and biology of Tissue Factor Pathway Inhibitor-2 (TFPI-2). The key objectives of this award are to: 1) delineate the specific residues and segments of the TFPI-2 Kunitz Domain 1 (KD1) that confer protease specificity for plasmin, Factor XIa, and...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $434,658 to Oakland University to conduct research on the intracellular function of the platelet protein TREM-like transcript-1 (TLT-1). The research aims to characterize the phosphorylation sites of TLT-1 and decipher the intracellular cues that regulate its trafficking in platelets. The...
- This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $445,500.00 in funding to Cleveland State University (CSU) for a project titled "Chemoenzymatic Semisynthesis of Proteoglycan and Its Cofactor Activities." The project aims to investigate the role of the proteoglycan thrombomodulin (TM) and its chondroitin sulfate glycosaminoglycan (CS-GAG) component in regulating the activation of protein C and...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research), provides $787,021 to The Leland Stanford Junior University (Stanford University) from September 20, 2025 through June 30, 2030. The grant supports research aimed at understanding the mechanisms of Factor VIII inhibitor formation in persons with hemophilia A, with the long-term goal of developing targeted therapies to prevent inhibitor development during early...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $151,523 to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating inflammation and thrombus resolution in acute and chronic venous thrombosis. The research aims to develop a novel RNA therapy using lipid nanoparticles to selectively reduce circulating fibrinogen levels and elucidate its impact on thromboinflammatory processes....
- This Project Grant award of $558,697 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at East Carolina University (ECU) to identify molecular signatures that differentiate fibrin and fibrinogen. The objective is to enable improved clinical diagnosis and therapeutic targeting of fibrin-related pathologies. The research will train the next generation of interdisciplinary scientists in molecular biology, biophysics, and biochemistry...
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...
- This Project Grant award for $713,538 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate metabolic reprogramming as a novel therapeutic approach for thrombotic cardiovascular disease. The key objectives are to explore how inhibiting the cytosolic malic enzyme 1 (ME1) in platelets and leukocytes can reduce their hyperactivation and susceptibility to arterial thrombosis, while minimizing bleeding risk compared to...
- This $601,169 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to better understand the molecular pathogenesis of myeloproliferative neoplasms (MPNs) and identify new therapeutic targets. Key focus areas include investigating the role of the PTPN1 tumor suppressor gene in MPN progression and the aberrant expression of TIMP-1 in MPN/myelofibrosis. The research is being conducted by the Rector & Visitors...